HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (14) Citing Articles via Google Scholar Google Scholar Articles by Durrington, P. N. Search for Related Content PubMed PubMed Citation Articles by Durrington, P. N. Related Collections Nutrition Proteomics and Protein Markers Lipids, Lipoproteins, and Cardiovascular Risk Factors Endocrinology and Metabolism

Can Measurement of Apolipoprotein B Replace the Lipid Profile in the Follow-up of Patients with Lipoprotein Disorders?

¹ Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, United Kingdom

Apolipoprotein B (apo B) was so called because it was the principal protein found in ß lipoprotein (LDL). It was later discovered that it is the major protein component of chylomicrons, chylomicron remnants, VLDL, intermediate density lipoprotein, LDL, and lipoprotein(a); it is absent from HDL. Thus apo B is present in lipoproteins that are potentially atherogenic and absent from those that are antiatherogenic. This prompted Fredrickson to write in 1974, "Its resistance to characterization, its seeming essentiality for glyceride transport, and perhaps the added suspicion that it has something to do with atherogenesis have all transformed apo B into one of the central mysteries of lipoprotein physiology" (1). This statement was remarkably prescient; apo B proved to be essential for hepatic and intestinal triglyceride secretion and for LDL catabolism and to be intimately involved in atherogenesis.

In the human, circulating hepatic apo B has 4536 amino acids and a molecular mass of 540 000 Da, whereas intestinal apo B present in chylomicrons has a molecular mass that is 48% that of hepatic apo B (2). Hence hepatic and intestinal apo B are termed apo B₁₀₀ and apo B₄₈, respectively. Both are the products of a single gene, but its message is edited in the enterocyte after translation of the N-terminal 2152 codons representing the amino acid sequences necessary for triglyceride-rich lipoprotein assembly and secretion. Hepatic and intestinal steatosis occur both in a-ß-lipoproteinemia (reflecting mutation of the microsomal triglyceride transfer protein, which allows apo B to associate physically with triglycerides in the liver and gut) and in homozygous hypo-ß-lipoproteinemia when mutations truncate apo B early in its sequence (2). The additional part of the molecule present in . . . [Full Text of this Article]

References

The following articles in journals at HighWire Press have cited this article:

				C. M. Ballantyne, J. S. Raichlen, and V. A. Cain Statin Therapy Alters the Relationship Between Apolipoprotein B and Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Targets in High-Risk Patients: The MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY II) Trial J. Am. Coll. Cardiol., August 19, 2008; 52(8): 626 - 632. [Abstract] [Full Text] [PDF]